(Health-NewsWire.Net, March 19, 2019 ) According to research report thrombectomy devices market is estimated to reach USD 1.45 billion by 2022; growing at a CAGR of 6.7% during the forecast period.
The key players focused on various strategies such as product launches and enhancements; agreements and collaborations; strategic acquisitions; and expansions to increase their shares in the global thrombectomy devices market. Product launches & enhancements is the strategy adopted by major industry players to achieve the desired market growth during 2013-2017. This strategy was adopted by Stryker Corporation (U.S.), Medtronic plc (Ireland), Boston Scientific Corporation (U.S.), Johnson & Johnson (U.S.), Terumo Corporation (Japan), Penumbra, Inc. (U.S.), Spectranetics Corporation (U.S.), Edwards Lifesciences Corporation (U.S.), Argon Medical Devices, Inc. (U.S.), and Teleflex Incorporated (U.S.). Apart from product launches and enhancements, many prominent players also adopted agreements and collaborations as their key growth strategy to strengthen their market presence, enhance their R&D capabilities, and to expand their distribution networks to generate additional demand by sensitizing end users through an increase in availability of thrombectomy devices.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222966801
Stryker Corporation held the leading position in the market in 2016. The company offers its thrombectomy devices through the Neurotechnology & Spine segment. The company has a strong presence in North America, Europe, the Middle East, Africa, Asia-Pacific and other countries. The company has more than 30 manufacturing facilities in countries such as the U.S., China, Turkey, Germany, Ireland, Switzerland, and France. It primarily focuses on growth strategies such as product development & commercialization, acquisitions, and market expansions. The market has witnessed several product launches & commercialization, expansions, and acquisitions by Stryker Corporation (U.S.) in the last three years. For instance, in 2016, the company commercialized thrombectomy devices such as Trevo Provue retriever and Trevo XP ProVue retriever, the establishment of its European headquarters in Amsterdam (Netherlands), in 2015, and the acquisition of Trauson Holdings Company Limited (China) in 2013. These developments strengthened its R&D capabilities and expanded its product portfolio in the market.
Medtronic plc is one of the prominent players in the market, in 2016. The company has a strong foothold in the market with a broad range of thrombectomy products. The company has a strong geographic presence across Asia-Pacific, Eastern Europe, Latin America, the Middle East & Africa, Central Asia, Western Europe, South Asia, and North America. To strengthen its current position and to gain a larger share in the market, the company aggressively focuses on growth strategies such as acquisitions and market expansions. During 2012–2016, the company established its training and research facility—Covidien Center of Innovation Brazil—in Brazil and its R&D, training, and education center—Covidien Center of Innovation Korea—in South Korea to enhance its R&D capabilities and expand its product portfolio and market presence in the market. The company also focuses on product commercialization as its business strategy. It commercialized thrombectomy devices such as the Solitaire stent retriever device in 2016 and Solitaire revascularization device in 2012.
Know more: https://www.marketsandmarkets.com/Market-Reports/thrombectomy-devices-market-222966801.html
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
Mr. Shelly Singh